Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azirkitug + bevacizumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Azirkitug + bevacizumab is an investigational combination of two monoclonal antibodies for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and other cancers. **Azirkitug (ABBV-514)** is a fully human monoclonal antibody that acts as a **CCR8 inhibitor**, blocking the C-C motif chemokine receptor 8, which may reduce immunosuppressive regulatory T cell (Treg) function in the tumor microenvironment. **Bevacizumab (Avastin)** is an established recombinant, humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby suppressing angiogenesis required for tumor growth. This combination aims to target both the immune microenvironment and angiogenesis in cancer, and is currently being developed by AbbVie. It is administered intravenously and is being evaluated in Phase 1 clinical trials for a variety of solid malignancies[1][2][3].
- Brand names
- Avastin
- Other names
- ABBV-514ABBV514ABBV 514azirkitugbevacizumab
02
Targets
Beyond the preview
Go deeper on azirkitug + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azirkitug + bevacizumab.